All data are based on the daily closing price as of April 1, 2025
c

Chugai Pharmaceutical

4519.TSE
45.37 USD
-0.23
-0.50%

Overview

Last close
45.37 usd
Market cap
74.66B usd
52 week high
52.91 usd
52 week low
28.34 usd
Target price
52.38 usd

Valuation

P/E
28.9479
Forward P/E
26.738
Price/Sales
9.915
Price/Book Value
5.8837
Enterprise Value
68.12B usd
EV/Revenue
8.7062
EV/EBITDA
18.8036

Key financials

Revenue TTM
7.82B usd
Gross Profit TTM
5.56B usd
EBITDA TTM
3.80B usd
Earnings per Share
1.57 usd
Dividend
0.66 usd
Total assets
14.13B usd
Net debt
-3.46B usd

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
  • Symbol
    4519.TSE
  • Exchange
    TSE
  • Isin
    JP3519400000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Dr. Osamu Okuda
  • Headquarter
    Chuo
  • Web site
    https://www.chugai-pharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top